Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2020 December;62(4) > Panminerva Medica 2020 December;62(4):225-33

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

SPECIAL ARTICLE  MULTIPLE MYELOMA IN 2020: STATE OF THE ART (PART I) Freefree

Panminerva Medica 2020 December;62(4):225-33

DOI: 10.23736/S0031-0808.20.04117-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Current and future perspectives of maintenance therapy in multiple myeloma

Chandramouli NAGARAJAN 1, 2 , Melinda S. TAN 1, Yunxin CHEN 1, 2, Giovanni MARTINELLI 3, Claudio CERCHIONE 3

1 Department of Hematology, Singapore General Hospital, Singapore, Singapore; 2 SingHealth Duke NUS Blood Cancer Center, Singapore, Singapore; 3 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



While the outcome of patients with multiple myeloma has significantly improved over the last two decades, the disease remains incurable for the majority of patients. With the advent of novel agents, there has been a shift towards prolonged therapy as opposed to fixed-duration therapy, aimed at improving progression-free survival and overall survival. Evidence favoring continuous therapy has emerged over the last 2 decades and in the context of maintenance after proteasome inhibitor plus immunomodulatory drug induction followed by high dose melphalan and stem cell transplantation, this leads to >80% overall survival at 5 years. Maintenance therapy specifically has been demonstrated to correlate with increasing depth of disease response with a significant proportion of patients who remain minimal residual disease positive at the end of induction therapy achieving minimal residual disease negativity with maintenance therapy both in clinical trials and selected real world populations. As the survival improves, it is crucial to identify patients who are projected to have better survival and spare them toxicities arising from indefinite maintenance therapy. The role of minimal residual disease in this context is being investigated in numerous clinical trials and in the next few years the goal should be to use this in a rational way to achieve the ability to identify patients who would require continuation or escalation of therapy to improve their projected survival as well as to identify the group of patients in whom maintenance therapy could perhaps be time-limited without compromising their survival. Here we review the evidence for maintenance therapy from the key trials in the past years, present an overview of the current landscape and our perspective of maintenance therapy in the future.


KEY WORDS: Multiple myeloma; Therapeutics; Maintenance

top of page